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Abstract
Objective
To determine the accuracy of automated detection of generalized tonic-clonic seizures (GTCS)
using a wearable surface EMG device.
Methods
We prospectively tested the technical performance and diagnostic accuracy of real-time seizure
detection using a wearable surface EMG device. The seizure detection algorithm and the cutoﬀ
values were prespeciﬁed. A total of 71 patients, referred to long-term video-EEGmonitoring, on
suspicion of GTCS, were recruited in 3 centers. Seizure detection was real-time and fully
automated. The reference standard was the evaluation of video-EEG recordings by trained
experts, who were blinded to data from the device. Reading the seizure logs from the device was
done blinded to all other data.
Results
The mean recording time per patient was 53.18 hours. Total recording time was 3735.5 hours,
and device deﬁciency time was 193 hours (4.9% of the total time the device was turned on). No
adverse events occurred. The sensitivity of the wearable device was 93.8% (30 out of 32 GTCS
were detected). Median seizure detection latency was 9 seconds (range −4 to 48 seconds). False
alarm rate was 0.67/d.
Conclusions
The performance of the wearable EMG device fulﬁlled the requirements of patients: it detected
GTCS with a sensitivity exceeding 90% and detection latency within 30 seconds.
Classification of evidence
This study provides Class II evidence that for people with a history of GTCS, a wearable EMG
device accurately detects GTCS (sensitivity 93.8%, false alarm rate 0.67/d).
MORE ONLINE
Class of evidence
Criteria for rating
therapeutic and diagnostic
studies
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Generalized tonic-clonic seizures (GTCS) may lead to inju-
ries, and constitute the major risk factor for sudden un-
expected death in epilepsy (SUDEP), especially in
unattended patients.1,2 Wearable seizure detection devices
were suggested to prevent SUDEP.1–4 The unpredictability of
seizure occurrence is distressing for patients and caregivers.3 It
contributes to social isolation and decreased quality of life,
and surveys showed a need for wearable seizure detection
devices.5–10
Therapeutic decisions and clinical trials use self-reporting of
seizures. However, this is unreliable: studies in video-EEG
monitoring units demonstrated that 61% of seizures remain
unrecognized by patients, even secondarily generalized tonic-
clonic seizures, which remained completely unrecognized.11
Wearable devices could provide objective data about seizure
occurrence.
Signals frommuscles, recorded with surface EMG, seem to be
a promising modality for detecting motor seizures. A recently
published review summarizes the speciﬁc pathophysiologic
changes in muscle activity during seizures.12 Quantitative
EMG parameters diﬀerentiate epileptic from physiologic
muscle activation and from nonepileptic seizures.13–15 Based
on characteristic changes in frequency and amplitude,16 we
have developed a generic seizure detection algorithm.17 High
sensitivity and speciﬁcity of EMG-based seizure detection
algorithms were found in 2 retrospective studies using oﬄine
analysis of EMG recorded with conventional ampliﬁers.17,18 A
pilot study showed promising results for a wearable EMG-
based device implementing our algorithm.19
We present a prospective, multicenter study on the diagnostic
accuracy of real-time detection of GTCS using the wearable
EMG device. We report our ﬁndings according to the Stand-
ards for Reporting of Diagnostic Accuracy (STARD) criteria.20
Methods
Patients
Seventy-one consecutive patients (32 female; age 10–62
years, mean 34.1 years, median 34 years) were recruited to the
study: 33 patients at the Danish Epilepsy Centre, Dianalund;
5 patients at Copenhagen University Hospital Rigshospitalet,
Denmark; and 33 patients at the National Centre for Epilepsy,
Oslo University Hospital, Norway, between October 21,
2014, and January 23, 2017. The median baseline monthly
frequency of GTCS according to the patients’ seizure logs
was 1.75.
Inclusion criteria were (1) admission to noninvasive long-
term video-EEG monitoring in the epilepsy monitoring unit
(EMU) in one of the participating centers; and (2) historical
data suggesting that the patient had GTCS. Exclusion criteria
were (1) age under 3 years; (2) pregnancy; (3) allergy to the
self-adhesive patch; or (4) implanted vagal nerve stimulator or
deep brain stimulator.
Patients underwent video-EEG monitoring using wireless
ampliﬁers (at the Danish Epilepsy Centre) or connected with
a 10-meter-long cable (in the other centers). The mobility of
the patients was not restricted in the EMUs, where patients
were free to perform their habitual physical activities and
participate in activities such as using an exercise bicycle,
preparing coﬀee or food, and playing home video games in-
volving body motion (Nintendo [Kyoto, Japan] Wii).21
Patients were under continuous surveillance and no injuries
occurred during monitoring.
Standard protocol approvals, registrations,
and patient consent
The project has been approved by the regional ethics com-
mittees (in Denmark: SJ-380; in Norway: 2013/2354). All
patients (or guardians of patients) gave their written, in-
formed consent prior to the study.
Wearable EMG-based seizure detection device
We tested the diagnostic accuracy of the Epileptic seizure
Detector Developed by IctalCare (EDDI). The device
measures surface EMG signals and was placed on the brachial
biceps muscle (ﬁgure 1, A–D). The device is relatively small,
and is easily hidden under the patient’s clothes. The choice of
side for the placement was decided based on historical data
where the patient’s seizures habitually were most strongly
expressed. When there was no known side preponderance, the
device was placed on the left.
The wearable device is attached to a self-adhesive hypoaller-
genic hydrogel patch (Axelgaard Manufacturing Co. Ltd.,
Fallbrook, CA) with 3 embedded surface EMG electrodes
(bipolar recording electrodes and ground electrode), de-
veloped speciﬁcally for this device (ﬁgure 1C). The distance
between the recording electrodes was 20 mm. A lithium
polymer battery was placed into the wearable device.
Sampling frequency was 1,024 Hz. A modiﬁed version of the
previously reported algorithm was implemented into the
device.17,19 Brieﬂy, the electrophysiologic biomarker of the
initial phase of GTCS consists of an increase in amplitude and
high-frequency (>150 Hz) oscillations in the EMG signal.
Glossary
CI = conﬁdence interval; EDDI = Epileptic seizure Detector Developed by IctalCare; EMU = epilepsy monitoring unit; FAR =
false alarm rate; GTCS = generalized tonic-clonic seizures; STARD = Standards for Reporting of Diagnostic Accuracy;
SUDEP = sudden unexpected death in epilepsy.
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This was expressed as the number of zero-crossings, where
high frequency oscillations (high-pass ﬁltered at 150 Hz)
exceeded a hysteresis of ±35 μV. The count of zero-crossings
was calculated for a window of 1 second, with an overlap of
75% with the previous window. When this exceeded the
predeﬁned threshold, the alarm was triggered (ﬁgure 2). The
measures are generic (not patient-speciﬁc), they were pre-
speciﬁed before this study, and they were applied to all
patients. The algorithm requires minimal computational
power.
The device gives real-time seizure alarms and a diﬀerent type
of alarm for device deﬁciency, when electrode impedance is
out of bounds. However, the study design implied blinding of
the personnel for any data from the device, and therefore these
alarms were disabled in this study. Instead, the device logged
real-time all-seizure alarm time points, for comparison with the
reference standard, and the periods with high impedance and
50-Hz artefacts were considered device deﬁciency periods.
Detected seizure time points were read blinded to any other
data. In addition, the EMG recorded by EDDI was transmitted
via radio signals to a computer that stored the signals. The
intention was to use these signals for further optimization and
ﬁne-tuning themeasures of the algorithm. However, that is not
reported in this study. All data presented in this study are based
on real-time seizure detection using the predeﬁned measures
and the algorithm described above, with all calculations done
on the wearable device.
The self-adhesive patch was changed once per day (standard
procedure). The battery was changed 3 times per day; this is
more than the standard procedure for the device, and it was
necessary because in the study EMG data were transmitted to
and saved on a computer. This increased signiﬁcantly the
power consumption of the device. For standard operation of
EDDI (real-time computation, giving alarms and logging time
points, without transmitting EMGdata), change of the battery
is required once per day.
Reference standard
The reference standard for identifying seizures was long-term
video-EEG monitoring, reviewed by trained, board-certiﬁed
clinical neurophysiologists and epileptologists, with more
than 10 years’ experience with EMU (S.B., O.H., and M.F.).
The experts were blinded to all data from EDDI, until they
completed the analysis of the video-EEG recordings. For
GTCS, they identiﬁed the start time point at the beginning of
the tonic phase and the end time point at the end of the clonic
phase. The time points of the reference standard were then
compared with the logs of the real-time automated seizure
Figure 1Wearable seizure detection device (Epileptic seizure Detector Developed by IctalCare)
(A) The wearable device placed on the brachial biceps muscles. (B, C) The wearable device, which is connected to the self-adhesive patch, containing the
recording electrodes and the ground electrode. (D) Remote control of the device.
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detection. At the beginning of each monitoring, the times in
the device and in the video-EEG monitoring equipment were
synchronized.
Study outcome measures
The primary aim was determining the diagnostic accuracy of
the device. Sensitivity was expressed as the percentage of the
detected GTCS. Speciﬁcity was expressed as the false alarm
rate (FAR), calculated from the entire patient population.
In addition, we documented the following: adverse events
(any patient concern related to the device, reported by the
patient or observed by the personnel), device-oﬀ time (total
time when the device was turned oﬀ during monitoring—for
example, for changing patch and battery, time in bathroom,
ictal SPECT), device-deﬁciency time (periods with high im-
pedance and artefacts preventing the functioning of the de-
vice; this was expressed as percentage of the total time when
the device was turned on—i.e., the total recording time), and
detection latency (measured from the start time point iden-
tiﬁed by the experts to the alarm time point from the device).
Classification of evidence
The primary research question was the accuracy (sensitivity
and false-alarm rate) of a wearable EMG device for detecting
GTCS. This study provides Class II evidence that for people
with a history of GTCS, the wearable EMG device, EDDI,
detects GTCSwith a sensitivity of 93.8% and a false-alarm rate
of 0.67/d.
Sample size estimation
For the expected sensitivity of 95%17,19 and expected preva-
lence of 28% in the studied population,22 with a conﬁdence
interval (CI) of 10%, we needed 18 patients with GTCS and 65
recruited patients.23 GTCS is the seizure type with the highest
risk for the patients and therefore considered an undesired
event in EMUs.24 Diagnostic tapering of antiepileptic medica-
tion is aimed at increasing seizure frequency though avoiding
GTCS unless this is the targeted seizure type, and these occur
relatively rarely in EMUs. Our intention was to record GTCS
from 20 patients, with a total of at least 30 GTCS. Since the
quantitative EMG changes during GTCS have a high intra-
individual and interindividual consistency, this number seemed
to be suﬃcient to evaluate the performance of the device.14
Results
The mean recording time per patient was 53.18 hours (me-
dian 53.12; range 2.3–130 hours). The device was turned on
for 3,928.6 hours. Device deﬁciency occurred in 193.1 hours
(4.9%). The total recording time was 3,735.5 hours. No ad-
verse events occurred.
Figure 3 shows the STARD ﬂowchart of the study. Thirty-two
GTCS occurred during the recording time. Twenty of the 71
included patients had GTCS (11 patients had 1 seizure each;
6 patients had 2 seizures; 3 patients had 3 seizures).
The sensitivity of the device was 93.8% as it detected 30 out of
the 32 GTCS (95% CI 86%–100%). All GTCS were detected
in 18 patients (90% of all patients with GTCS). Two patients
with 2 seizures had only 1 seizure detected. Calculated per
patient, the mean sensitivity was 95% (median 100%; range
50%–100%). Four seizures from 3 patients with idiopathic
generalized epilepsy were primary GTCS; all of them were
detected. The other seizures were secondarily GTCS.
Both missed GTCS occurred as the second seizure after
a detected GTCS, with short interseizure periods (19 minutes
and 98 minutes, respectively). Retrospective inspection of the
EMG signals during the missed seizures showed low amplitude
of the EMG signal in one case, and very short tonic phase in the
other case, so that the number of zero-crossings did not exceed
the predeﬁned detection threshold for any of themissed seizures.
The median detection latency of the device was 9 seconds
(range −4 to 48 seconds; mean 12.3 seconds), measured from
the start of the tonic phase of the seizures.
Figure 2 EMG-based seizure detection algorithm
(A) The EMG signals recorded by Epileptic seizure Detector Developed by
IctalCare (EDDI) during a generalized tonic-clonic seizure (high-pass filter:
150 Hz). (B) The number of zero-crossings calculated from the signal in (A).
The horizontal axis in both (A) and (B) is the time (in seconds). When the
number of zero-crossings exceeds the threshold (dotted horizontal line) for
the prespecified time window (yellow line), then the seizure alarm is trig-
gered (red vertical arrow).
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The false discovery rate was 0.02/h (i.e., 0.67/d). Two-
thirds of the patients (47/71 [66%]) did not have false
alarms. In 3 patients, the number of false alarms was ≥10.
The most common reason for false alarms was physiologic
muscle activation: physical exercise (68% of false alarms).
The second most common reason was device malfunction:
induction artifacts (18%) and detaching electrodes (2.5%).
The vast majority of false alarms occurred during daytime.
Only 2 nocturnal false alarms occurred: one was triggered
by an episode classiﬁed as paroxysmal arousal, and the
other one was triggered by stretching the arms during an
arousal.
The ratio between false alarms and true alarms was ≤1 for
17 of the 20 patients with GTCS (85%), and in 13 patients
with GTCS (65%) the ratio was zero (i.e., no false alarms
recorded). The range of the ratio was between 0 and 14
(median 0; mean 1.3). A total of 161 seizures other than
GTCS occurred during the recording: 59 simple partial
seizures (11 patients), 55 complex partial seizures (14
patients), 26 myoclonic jerks (5 patients), 6 absences (2
patients), 1 nonconvulsive status epilepticus, 14 convulsive
psychogenic nonepileptic seizures (5 patients). None of
these triggered seizure alarms.
Discussion
In this prospective, multicenter, blinded study on the accuracy of
real-time detection of GTCS using an EMG-based wearable
device (EDDI), we found that it had high sensitivity (93.8%) and
short detection latency (9 seconds). Speciﬁcity of the device was
reﬂected by the low number of false alarms (0.67/d). None of
161 seizures other than GTCS triggered an alarm.
As the study was blinded, the alarm function of the device was
turned oﬀ in this study. Nevertheless, the short detection
latency suggests that timely warning is possible using this
device. Large ﬁeld studies, with long-term, ambulatory use of
the device, are necessary to evaluate its potential in reducing
the number of seizure-related injuries and ultimately the
number of SUDEP.
Both undetected seizures occurred shortly after a detected
GTCS. A possible explanation is that the mechanism of
Figure 3 Standards for Reporting of Diagnostic Accuracy flowchart of the study
DBS = deep brain stimulation; EDDI = Epileptic seizure Detector Developed by IctalCare; GTCS = generalized tonic-clonic seizure.
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muscle activation during the tonic phase of recurring GTCS is
diﬀerent (smaller amplitude, shorter duration). Multiple
GTCS occurred in 7 other patients in whom all GTCS were
detected. Recurring seizures (i.e., with short interseizure pe-
riod) occurred in the group of detected seizures too. Two
of the detected, recurring seizures had interseizure periods
(73 and 74 minutes) within the range of the interseizure
periods of the undetected seizures (19–98 minutes). Thus, in
at least some patients the second GTCS might remain un-
detected, when the interseizure period is short.
Surveys of large numbers of patients and their caregivers
addressed the users’ requirements for wearable seizure detection
devices.7–10 Patients did not want to use implanted and EEG-
based devices. Patch electrodes at invisible body sites were
considered acceptable.7,8,10 Detection of seizures involving heavy
movement and falls was considered most important by patients
and caregivers, while for physicians, SUDEP prevention was the
most signiﬁcant goal.8 This emphasizes the importance of
detecting GTCS, the seizure type that is targeted by our device.
The most important feature for users was sensitivity, with most
users requiring sensitivity over 90%. Our device provides this.
The required detection latency was under 10 seconds8 or 30
seconds.9 The median detection latency in our study was 9
seconds. In 2 cases, the muscle activation triggering the alarm
occurred 3–4 seconds before any movement was observable in
the video-EEG recordings, giving negative values for detection
latency. Concerning the FAR, the results of the surveys varied
broadly, but in all surveys users agreed that sensitivity is more
important than FAR. In one of the surveys, the acceptable FAR
was considered less than 1/wk or up to 1 false alarm/detected
seizure.8 Our device fulﬁlled the latter requirement, but the
overall FAR was more than 1/wk (4.7/wk). However,
throughout the study, only 2 false alarms occurred during sleep,
which is important for the quality of life of patients and
caregivers.
The baseline frequency of GTCS prior to admission to the
EMU was lower than what we recorded in the EMU. This
means that in ambulatory use, the ratio between false alarms
and true alarms would be higher than what we calculated in
the EMU, and FAR may need to be improved for ambulatory
use in medicated patients. Nevertheless, the baseline seizure
frequency of GTCS was derived from the patients’ seizure
logs, and previous studies showed that many GTCS remain
undetected by the patients.11
Device deﬁciency time was <5%. The device gives alarms
when the electrode impedance is too high, so that the users
can correct this. However, due to the blinding, this feature was
disabled throughout the study. Thus, it is reasonable to as-
sume that device deﬁciency time would be shorter when users
are alerted about this.
Two diﬀerent algorithms for unimodal EMG-based seizure
detection have been developed by 2 groups. Both algorithms
have been tested retrospectively, by oﬄine analysis of data
recorded with conventional ampliﬁers.17,18 Our algorithm is
generic and targets the initial phase of GTCS.17 The retro-
spective oﬄine analysis gave a sensitivity of 100%. A modiﬁed
version of this algorithm was implemented in the wearable
device we have tested. In this prospective study, based on real-
time seizure detection, 2 of the 32 seizures were missed. This
demonstrates the importance of validating seizure detection
devices using this design, rather than by oﬄine, retrospective
analysis. The other algorithm, developed by Brain Sentinel
(San Antonio, TX), targets a later phase: the tonic–clonic
interface.18 The algorithm is individualized and it utilizes the
Hotelling T2 power analysis. The retrospective, oﬄine anal-
ysis showed a sensitivity of 95% (20 out of 21 GTCS from 11
patients were detected) and only 1 false alarm occurred. The
average detection latency was within 20 seconds.18 Both
algorithms have been registered for medical application: in
Europe, EDDI obtained CE registration in 2013, and Brain
Sentinel was granted de novo clearance by the Food and Drug
Administration in 2017.
In spite of numerous attempts to develop noninvasive seizure
detection,3,5 there are only 4 prospective studies on clinical val-
idation of wearable devices using real-time seizure
detection.22,25–27 All 4 studies used accelerometers. Two articles
addressed the same device: SmartWatch.26,27 Although the pilot
study showed promising results (7 out of 8 seizures were
detected),26 in a large prospective study, only 31% of GTCS
were detected.27 Another algorithm correctly identiﬁed 20 of 22
(91%) seizures from 15 patients, and had a detection latency of
17 seconds.25 Although real-time, the analysis was done on
a computer placed within 10meters from the patient. A wearable
accelerometer device (Epi-Care Free; Tunstall, Astoria, NY)
detected GTCS with a sensitivity of 89.7%.22 Although the FAR
was low (0.2/d), this was achieved by instructing patients to
avoid movements that could trigger alarms with the arm where
the sensor was placed. The detection latency was signiﬁcantly
longer (55 seconds) compared to EDDI. Accelerometers trigger
the alarm in the later, clonic phase of the GTCS, while EDDI
targets the initial part of the tonic phase, thus providing much
earlier detection (9 seconds) of the seizure and the possibility of
much earlier intervention.
The main limitation of our study is the intrinsic challenge of
any validation study of wearable seizure detection devices: the
testing was done in an EMU, which diﬀers from the patients’
home environment. This was necessary in order to have the
reference standard. However, mobility of the patients was not
restricted during monitoring, and they were encouraged to
perform indoors physical activities similar to their habitual
lifestyle.21
Using the data recorded in this study, further optimization of
the algorithm is planned, especially for decreasing the FAR.
An alternative approach can be using individualized thresh-
olds. It is noteworthy that the device was not triggered by any
of the 14 convulsive psychogenic nonepileptic seizures that
occurred during this study, considering that all 5 patients who
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had these were referred to the EMU on suspicion of GTCS.
This raised the possibility of using the device for diﬀerential
diagnostic purposes, as indicated previously.15
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